Rapport Therapeutics RAPP
NASDAQ RAPP
$26.48 -0.54 (-2.00%)
As of: Nov 12, 2026 · 2:09 PM EST

Rapport Therapeutics (RAPP) Sales of Property, Plant and Equipment (2026)

Updated

Analysis

Rapport Therapeutics (RAPP) Sales of Property, Plant and Equipment (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PP&E (Sale) (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -4.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Rapport Therapeutics 1.25 Bn 853.38 Mn - 208,000.00
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 208,000.00
API Access

Rapport Therapeutics Sales of Property, Plant and Equipment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=sales-of-property-plant-and-equipment&ticker=RAPP&period=max&api_key=YOUR_API_KEY